Who to call at Prelude Therapeutics Incorporated, and when
Fundz watches for the moments Prelude Therapeutics Incorporated starts buying, and tells you who to reach.
- An alert the day Prelude Therapeutics Incorporated raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Prelude Therapeutics Incorporated, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Prelude Therapeutics Incorporated. With Fundz connected, it knows.
Prelude Therapeutics Incorporated
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
AI Executive Summary
AI-powered analysis of 8-K filing content
Prelude Therapeutics director Mardi Dier resigned from the Board effective October 17, 2025, with no disagreement reported. The Board appointed Katina Dorton as a Class III director and Audit Committee member, and she will chair the committee.
Key Takeaways
Mardi Dier, a Class III director, resigned effective October 17, 2025. The filing states her decision was not the result of any disagreement with the Company on operations, policies, or practices.
Katina Dorton, J.D., MBA, was appointed a Class III director effective October 17, 2025, on the recommendation of the Nominating and Corporate Governance Committee. She will serve until the 2026 Annua
3 more takeaways
Related Filings (2)
2 more filings from Prelude Therapeutics Incorporated in the last 90 days
Filing Overview
What This Means
Prelude Therapeutics Incorporated filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.